NCT04657302 - A Study to Evaluate Glofitamab as Single Agent Administered After Pretreatment With Obinutuzumab in Chinese Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

January 8, 2021

Primary Completion Date

October 25, 2022

Study Completion Date

January 12, 2024

Conditions

Lymphoma

Interventions

DRUG

Obinutuzumab

Participants will receive 1000 mg of intravenous (IV) obinutuzumab on Cycle 1 Day 1.

DRUG

Glofitamab

Participants will receive 2.5 mg of IV glofitamab Cycle 1 Day 8, 10 mg at Cycle 1 Day 15, and 30 mg on Day 1 of Cycles 2-12 Q3W (cycle length = 21 days).

DRUG

Tocilizumab

Participants will receive tocilizumab as needed to manage cytokine release syndrome (CRS).

Trial Locations (6)

100142

Beijing Cancer Hospital, Beijing

100191

Peking University Third Hospital, Beijing

150081

Harbin Medical University Cancer Hospital, Harbin

210008

Jiangsu Province Hospital, Nanjing

300060

Tianjin Cancer Hospital, Tianjin

510060

Cancer Center, Sun Yat-sen University of Medical Sciences; Department of Medical Oncology, Guangzhou

All Listed Sponsors

lead

Hoffmann-La Roche

INDUSTRY